
### PHARMACEUTICAL 2019

# Orgenesis Inc. Rank 105 of 371







#### PHARMACEUTICAL 2019

## Orgenesis Inc. Rank 105 of 371



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 132% points. The greatest weakness of Orgenesis Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is -40%, being 291% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	30,297
Cost of Goods Sold	10,824
Intangible Assets	31,865
Liabilities, Current	17,145
Liabilities, Non-Current	5,500
Other Assets	1,384
Other Compr. Net Income	-187
Other Expenses	3,250
Other Liabilities	0
Other Net Income	-3,848
Property and Equipment	11,901
Research and Development	6,464
Revenues	21,585
Selling, General and Administrative Expense	16,303

Output Variable	Value in 1000 USD
Assets	75,447
Liabilities	22,645
Expenses	36,841
Stockholders Equity	52,802
Net Income	-19,104
Comprehensive Net Income	-19,198
Economic Capital Ratio	-40%